Job Boyad, head of the Kenya Anti-AIDS Vaccine Research Center, issued a statement in Nairobi, Kenya, on 28th, saying that the first-phase trial results of this anti-AIDS vaccine proved that it had no side effects on human body and could effectively stimulate human immune system. He said that the second phase of the six-month trial will begin in Kenya in the middle of next month. The third phase of the experiment will be carried out simultaneously in Kenya and Britain in early 2004. Boyade said that the vaccine can only be put into use after the successful completion of the third phase of the trial, and it will take 2-5 years to process and edit its data and experimental results. This was reported in 200 1 and should be released soon.